Dashboard
1
Poor Management Efficiency with a low ROCE of 17.69%
- The company has been able to generate a Return on Capital Employed (avg) of 17.69% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 0.32% and Operating profit at -16.67% over the last 5 years
4
Flat results in Jun 26
5
With ROE of 16.74%, it has a fair valuation with a 2.01 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 16,945 Million (Large Cap)
12.00
NA
3.55%
-0.16
16.74%
2.34
Revenue and Profits:
Net Sales:
805 Million
(Quarterly Results - Jun 2026)
Net Profit:
148 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.06%
0%
6.06%
6 Months
-8.49%
0%
-8.49%
1 Year
-3.67%
0%
-3.67%
2 Years
11.32%
0%
11.32%
3 Years
-25.75%
0%
-25.75%
4 Years
-9.85%
0%
-9.85%
5 Years
-26.99%
0%
-26.99%
Tonghua Dongbao Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.32%
EBIT Growth (5y)
-16.67%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
0.36
Tax Ratio
21.68%
Dividend Payout Ratio
47.66%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.65%
ROE (avg)
17.19%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
2.01
EV to EBIT
28.66
EV to EBITDA
19.41
EV to Capital Employed
2.20
EV to Sales
4.42
PEG Ratio
0.01
Dividend Yield
4.13%
ROCE (Latest)
7.66%
ROE (Latest)
16.74%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
805.20
747.70
7.69%
Operating Profit (PBDIT) excl Other Income
239.80
238.10
0.71%
Interest
5.10
3.90
30.77%
Exceptional Items
-0.20
0.00
Consolidate Net Profit
148.30
121.40
22.16%
Operating Profit Margin (Excl OI)
194.60%
207.30%
-1.27%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 7.69% vs -2.59% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 22.16% vs 1,205.38% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,937.40
2,004.10
46.57%
Operating Profit (PBDIT) excl Other Income
884.30
319.10
177.12%
Interest
22.00
14.90
47.65%
Exceptional Items
-177.20
-135.30
-30.97%
Consolidate Net Profit
1,197.20
-42.70
2,903.75%
Operating Profit Margin (Excl OI)
198.60%
56.90%
14.17%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 46.57% vs -34.72% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 2,903.75% vs -103.66% in Dec 2024
About Tonghua Dongbao Pharmaceutical Co., Ltd. 
Tonghua Dongbao Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






